Skip to content
Formerly ApoCell
  • Home
  • Who We Help
    • Biopharma
    • Academia & Government
    • Patients
    • Contract Research Organizations
  • What We Do
    • Services
      • Platform Technologies
      • Assay Development
      • Circulating Tumor Cells
      • Genomics
      • Flow Cytometry
      • FISH
      • Immunohistochemistry
      • Immunofluorescence Image Analysis
      • Cytokine Profiling
      • Clinical Sample Processing Services
      • Strategic Alliances
    • Areas of Expertise
      • Liquid Biopsy
      • Immuno-oncology
      • Companion Diagnostics
      • Clinical Trial Support
    • Case Studies
    • Test Menu
  • Technology
    • ApoStream Technology Platform
    • Partnering
  • News & Publications
    • Publications
    • Abstracts & Posters
    • Conferences
    • In the News
  • About Us
    • Management Team
    • Regulatory
    • Careers
  • Contact Us
    • Contact Us
    • Request for Proposal
Main Menu
Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D. J., McMahon, G., and Ellis, L. M. “Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.” Cancer Res., 59: 5412-5416, 1999.

Clinical Trial Research Publications

Home Clinical Trial Research Publications

Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D. J., McMahon, G., and Ellis, L. M. “Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.” Cancer Res., 59: 5412-5416, 1999.

  • External Link
Learn More

Liu, W., Davis, D.W., Ramirez, K., McConkey, D.J., and Ellis, L.M. “Endothelial Cell Apoptosis is Inhibited by a Soluble Factor Secreted by Human Colon Cancer Cells.” Int. J. Cancer, 92:26-30, 2001.

  • External Link
Learn More

McConkey, D.J., Davis, D.W. “Apoptosis and taxol therapy.” Cancer Biol Ther. 2002 Mar-Apr;1(2):118-20.

  • External Link
Learn More

Herbst R.S., Mullani N.A., Davis D.W., Hess K.R., McConkey D.J., Charnsangavej C., OReilly M.S., Kim H.W., Baker, C., Roach, J., Ellis L.M., Rashid, A., Pluda J., Bucana, C., Madden, T.L., Tran, H.T., Abbruzzese J.L. ” Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin.” J Clin Oncol. 2002 Sep 15;20(18):3804-14.

  • External Link
Learn More

Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. “Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.” Clin Cancer Res. 2003 Mar;9(3):955-60.

  • External Link
Learn More

Davis, D.W., McConkey, D.J., Wei Zhang, Herbst, R.S. “Antiangiogenic Tumor Therapy.” Antiangiogenic tumor therapy. Biotechniques. 2003 May;34(5):1048-50, 1052, 1054 passim. Review.

  • External Link
Learn More

Davis, D.W., McConkey, D.J., Abbruzzese, J.L., Herbst, R.S. “Surrogate markers in antiangiogenesis clinical trials.” Br J Cancer. 2003 Jul 7;89(1):8-14. Review.

  • External Link
Learn More

Davis, D.W., Shen, Y., Mullani, N.A., Wen, S., Herbst, R.S., OReilly, M.S., Abbruzzese, J.L., McConkey, D.J. “Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.” Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):33-42.

  • External Link
Learn More

Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. ” Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.” Cancer Res. 2004 Jul 1;64(13):4601-10.

  • External Link
Learn More

Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. ” Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.” Clin Cancer Res. 2004 Sep 1;10(17):5732-40.

  • External Link
Learn More
1 2 3 Next
<p><a href="https://www.precisionmedicinegrp.com/pfm/" rel="noopener" target="_blank"><img class="size-full wp-image-1031 alignnone" src="https://www.apocell.com/wp-content/uploads/2019/02/PFM-Footer-Logo.png" alt="" width="218" height="52" srcset="https://www.apocell.com/wp-content/uploads/2019/02/PFM-Footer-Logo.png 218w, https://www.apocell.com/wp-content/uploads/2019/02/PFM-Footer-Logo-100x24.png 100w" sizes="(max-width: 218px) 100vw, 218px" /></a></p> <p>Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patients more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution.</p>
  • Visit Precision for Medicine
  • Site Map
  • Privacy Policy
© Precision For Medicine, formerly ApoCell, 2019. All rights reserved.
  • Terms of Use
  • Privacy Policy
  • Site Map
By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts. For more information, or to learn how to change your cookies preferences, please click here.